This website is optimized for visualization with Firefox and Internet Explorer (8 or 9)

UNDERSTANDING LILLY'S CLINICAL DEVELOPMENT PIPELINE WEBSITE

Thank you for visiting Lilly’s Clinical Development Pipeline website. This interactive page is designed to help you better understand the information contained on the site, particularly as it relates to the molecules Lilly is currently developing for patients worldwide who are waiting. We encourage you to click on the content on this page – including the dates on the left, the abbreviations below and the terms in the legend to the right – for helpful definitions and background information. Additionally, below are responses to some frequently asked questions regarding the site’s information and how it is displayed. 

 

We hope that after exploring this page, you find Lilly’s Clinical Development Pipeline website educational and easy to navigate. 

Abbreviations

Frequently Asked Questions

Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 19, 2016. Lilly assumes no duty to update this information.

For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
  • NME
  • Select NILEX
  • Diagnostic